Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs taxane chemotherapy in refractory esophageal cancer
2015-003339-36Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in esophageal cancer (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Overall survival. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on 2015-003339-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003339-36.